Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GlaxoSmithKline plc (the “Company”) Directorate changes
Sir Deryck Maughan, Dr Stephanie Burns, Dr Daniel Podolsky and Hans Wijers will not stand for re-election to the Board at GSK’s AGM
-
GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of children aged 4-11 years with asthma
GSK today announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study.
-
GSK and Miltenyi Biotec establish cell and gene therapy collaboration
Collaboration includes discovery programme for CAR-T cell-based oncology therapies
-
GSK presents data at AAAAI on efficacy of Nucala® (mepolizumab) in severe asthma patients stratified by eosinophil levels
GSK today presented results at the American Academy of Allergy, Asthma & Immunology annual meeting from a post-hoc study
-
NEJM publishes results of GSK’s long-term LABA safety study of Advair ® Diskus® in adults and adolescents with asthma
GSK today announced publication of results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359)
-
GSK presents new data on the long-term efficacy & safety of Nucala® for the treatment of severe asthma with an eosinophilic phenotype
GSK today presented new safety and efficacy data for Nucala® (mepolizumab)
-
GSK names winners of 2015 Discovery Fast Track Challenge
Six winning proposals were selected from 378 entries submitted from 21 countries across Europe and North America
-
New long-term organ damage analysis published for GSK’s Benlysta® (belimumab)
Patients with SLE are at risk of irreversible organ damage which will accrue over time and is associated with increased risk of death1.
-
ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
-
ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
32 week maintenance data presented at CROI showed comparable viral suppression rates between injectable regimen and three drug oral regimen
-
Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
Healthcare Innovation Award is a major initiative within five-year partnership to help save one million children’s lives
-
GSK’s global HIV business ViiV Healthcare completes transactions to acquire Bristol-Myers Squibb’s R&D HIV assets
ViiV Healthcare has completed two previously announced transactions with Bristol-Myers Squibb
-
Results announcement for the fourth quarter 2015
GSK delivers further progress with 2015 sales of £24 billion (+6%), core EPS 75.7p (-15%) and total EPS 174.3p, +>100% CER 2016
-
GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 mos+
This vaccine is currently approved for active immunisation against influenza A subtype viruses and type B viruses
-
GSK and Adaptimmune expand strategic immunotherapy collaboration
GSK and Adaptimmune Therapeutics have expanded the terms of their strategic collaboration agreement
-
Global pharmaceutical industry calls on governments to work with them to beat the rising threat of drug resistance
Governments and industry called on to work in parallel in taking comprehensive action against drug-resistant infections
-
ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection
ViiV Healthcare, Pfizer Inc. and Shionogi Limited with Janssen for cabotegravir and rilpivirine for the treatment of HIV-1 infection.
-
GSK appoints Dr Jesse Goodman to the Board as a Non-Executive Director
Dr Jesse Goodman has been appointed to the Board of the Company as a Non-Executive Director and Scientific and Medical Expert
-
GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis
GSK announced completion of its divesting of rights to ofatumumab for auto-immune indications to Novartis Pharma following reg. approval.
-
GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets
Two transactions further strengthen HIV pipeline and outlook